Here are five things to know:
1. The UCLA board of regents approved the settlement in the case, paying $4.2 million to one patient and $4.25 million to a second patient who allege surgeries performed by Jeffrey Wang, MD, led to complications and additional operations. They allege Dr. Wang didn’t disclose off-label use of bone morphogenetic protein or his financial ties to Medtronic.
2. One of the patients also accused Medtronic of promoting off-label product use to the surgeon and hospital. However, Medtronic denied the charge.
3. Dr. Wang has left UCLA since these procedures were performed and now serves as co-director of USC Spine Center. Dr. Wang and USC Spine Center denied wrongdoing.
4. Medtronic denied promoting off-label use and denied wrongdoing; the company was dropped from one of the cases and agreed to a separate undisclosed settlement in the other. The company also claimed any payment Dr. Wang received from Medtronic wasn’t for the devices used in either case.
5. UCLA denied wrongdoing by physicians but wanted to avoid further litigation.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.